Mitochondrial Dysfunction in Alzheimer's Disease: Opportunities for Drug Development

Area of Science:

• Neuroscience
• Biochemistry
• Pathology

Background:

• Alzheimer's disease (AD) causes 60-80% of dementia cases, characterized by brain plaques and tangles leading to neurodegeneration.
• AD pathology includes abnormal microvasculature, inflammation, oxidative stress, and impaired metabolism.
• Mitochondrial Dysfunction (MD) is implicated in all major AD pathologies, regardless of its causal role.

Purpose of the Study:

• To review pre-clinical and clinical evidence linking MD to AD neurodegeneration.
• To establish MD as a critical mediator in AD progression.
• To encourage the development of MD-targeted drugs for AD management.

Main Methods:

• Review of existing scientific literature.
• Analysis of pre-clinical and clinical studies on Alzheimer's disease and mitochondrial function.
• Synthesis of evidence connecting mitochondrial malfunction to neurodegenerative processes in AD.

Main Results:

• Altered mitochondrial morphology, distribution, and movement are observed in AD.
• Increased oxidative stress, impaired metabolism, and reduced mitochondrial biogenesis are evident in AD subjects.
• MD is consistently associated with neurodegeneration and other AD pathologies.

Conclusions:

• Mitochondrial dysfunction is a central factor in the progression of Alzheimer's disease.
• Evidence strongly supports MD's role in AD neurodegeneration.
• Further research into MD-based therapies holds promise for AD treatment.